Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (264)	2/11/1999 3:55:00 PM
From: tuck	Read Replies (1) \| Respond to of 2515

CBS MarketWatch reporting from Cruttenden Roth Conference today . . Biotech company ImClone's (IMCL) chief financial officer said the company's lead anti-cancer drug, C225, is heading into Phase III trials in the next few weeks. In previous trials, Carl Goldfisher said, the drug was "remarkably safe" C225 serves as an antibody to block epidermal growth factor receptor, the market for which is in "the hundreds of millions of dollars," Goldfisher told an audience at the Cruttenden Roth Growth Stock Conference. The company will soon start to build a manufacturing plant with funding it received from Merck and will start producing C225, assuming Food and Drug Administration approval, in 18 months to two years. It will interesting to see if volume starts picking up . . . Cheers, Tuck